Innovative management of recurrent furunculosis

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 479-487

  Atanaskova, Natasha ^a   Tomecki, Kenneth J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Colonization; Furunculosis; Management; MRSA; Staphylococcus aureus

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; CHLORHEXIDINE; CLINDAMYCIN; COTRIMOXAZOLE; CRYSTAL VIOLET; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FUSIDIC ACID; LINEZOLID; MINOCYCLINE; ORITAVANCIN; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN; STAPHYLOCOCCUS VACCINE; STREPTOGRAMIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIOPHAGE; BACTERIUM CULTURE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CREATINE KINASE BLOOD LEVEL; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSESTHESIA; ERADICATION THERAPY; FURUNCULOSIS; GASTROINTESTINAL SYMPTOM; HAND WASHING; HUMAN; HYPERBILIRUBINEMIA; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYALGIA; NAUSEA; NECROTIZING FASCIITIS; OPTIC NERVE DISEASE; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QT PROLONGATION; RECURRENT INFECTION; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SKIN DECONTAMINATION; SYSTEMIC THERAPY; THROMBOPHLEBITIS; TOPICAL TREATMENT; URINARY TRACT INFECTION; VOMITING; WOUND DRAINAGE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CHILD; CLINICAL TRIALS AS TOPIC; DRAINAGE; FEMALE; FURUNCULOSIS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RECURRENCE; RISK FACTORS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; THERAPIES, INVESTIGATIONAL; YOUNG ADULT;

EID: 77953269941     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.013     Document Type: Review

References (73)

1. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41(10):1373-1406.
2. Taira B.R., Singer A.J., Thode H.C., et al. National epidemiology of cutaneous abscesses: 1996 to 2005. Am J Emerg Med 2009, 27(3):289-292.
3. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355(7):666-674.
4. El-Gilany A.H., Fathy H. Risk factors of recurrent furunculosis. Dermatol Online J 2009, 15(1):16.
5. Steele R.W. Recurrent staphylococcal infection in families. Arch Dermatol 1980, 116(2):189-190.
6. Shinefield H.R., Ruff N.L. Staphylococcal infections: a historical perspective. Infect Dis Clin North Am 2009, 23(1):1-15.
7. Abrahamian F.M., Talan D.A., Moran G.J. Management of skin and soft-tissue infections in the emergency department. Infect Dis Clin North Am 2008, 22(1):89-116. vi.
8. Stewart G.T., Holt R.J. Evolutio of natural resistance to the newer penicillins. Br Med J 1963, 1(5326):308-311.
9. Graffunder E.M., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002, 49(6):999-1005.
10. Whitman T.J. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Dis Mon 2008, 54(12):780-786.
11. Seybold U., Kourbatova E., Johnson J., et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006, 42(5):647-656.
12. Fridkin S.K., Hageman J.C., Morrison M., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352(14):1436-1444.
13. Baba T., Takeuchi F., Kuroda M., et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002, 359(9320):1819-1827.
14. Wisplinghoff H., Rosato A.E., Enright M.C., et al. Related clones containing SCCmec type IV predominate among clinically significant Staphylococcus epidermidis isolates. Antimicrob Agents Chemother 2003, 47(11):3574-3579.
15. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005, 40(1):100-107.
16. Meunier O., Falkenrodt A., Monteil H., et al. Application of flow cytometry in toxinology: pathophysiology of human polymorphonuclear leukocytes damaged by a pore-forming toxin from Staphylococcus aureus. Cytometry 1995, 21(3):241-247.
17. Hedstrom S.A. Recurrent staphylococcal furunculosis. Bacteriological findings and epidemiology in 100 cases. Scand J Infect Dis 1981, 13(2):115-119.
18. Cohen P.R. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol 2007, 8(5):259-270.
19. Leonard F.C., Markey B.K. Meticillin-resistant Staphylococcus aureus in animals: a review. Vet J 2008, 175(1):27-36.
20. Hoeger P.H. Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. Pediatr Allergy Immunol 2004, 15(5):474-477.
21. Demircay Z., Eksioglu-Demiralp E., Ergun T., et al. Phagocytosis and oxidative burst by neutrophils in patients with recurrent furunculosis. Br J Dermatol 1998, 138(6):1036-1038.
22. Dissemond J. Methicillin resistant Staphylococcus aureus (MRSA): diagnostic, clinical relevance and therapy. J Dtsch Dermatol Ges 2009, 7(6):544-551. [quiz: 552-3].
23. Murakami K., Minamide W., Wada K., et al. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. J Clin Microbiol 1991, 29(10):2240-2244.
24. Lee M.C., Rios A.M., Aten M.F., et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004, 23(2):123-127.
25. Krucke G.W., Grimes D.E., Grimes R.M., et al. Antibiotic resistance in Staphylococcus aureus-containing cutaneous abscesses of patients with HIV. Am J Emerg Med 2009, 27(3):344-347.
26. Rohana A.R., Rosli M.K., Nik Rizal N.Y., et al. Bilateral ophthalmic vein thrombosis secondary to nasal furunculosis. Orbit 2008, 27(3):215-217.
27. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36(1):53-59.
28. Paydar K.Z., Hansen S.L., Charlebois E.D., et al. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006, 141(9):850-854. [discussion: 855-6].
29. Moellering J., Robert C. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46(7):1032-1037.
30. Garau J., Bouza E., Chastre J., et al. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 2009, 15(2):125-136.
31. Daum R.S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007, 357(4):380-390.
32. Morgan M.S. Diagnosis and treatment of Panton-Valentine Leukocidin (PVL)-associated staphylococcal pneumonia. Int J Antimicrob Agents 2007, 30(4):289-296.
33. Ruhe J.J., Monson T., Bradsher R.W., et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005, 40(10):1429-1434.
34. Minuth J.N., Holmes T.M., Musher D.M. Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and -resistant staphylococci. Antimicrob Agents Chemother 1974, 6(4):411-414.
35. Han L.L., McDougal L.K., Gorwitz R.J., et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007, 45(4):1350-1352.
36. Kaka A.S., Rueda A.M., Shelburne S.A., et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006, 58(3):680-683.
37. Loeb M., Main C., Walker-Dilks C., et al. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003, (4). CD003340.
38. Besier S., Ludwig A., Brade V., et al. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol 2003, 47(2):463-469.
39. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44(9):1208-1215.
40. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003, 138(2):135-142.
41. Li Z., Willke R.J., Pinto L.A., et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001, 21(3):263-274.
42. Taylor J.J., Estes L.L., Wilson J.W. Linezolid and serotonergic drug interactions. Clin Infect Dis 2006, 43(10):1371.
43. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355(7):653-665.
44. Rose W.E., Leonard S.N., Sakoulas G., et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008, 52(3):831-836.
45. Mangili A., Bica I., Snydman D.R., et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005, 40(7):1058-1060.
46. Drew R.H., Perfect J.R., Srinath L., et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000, 46(5):775-784.
47. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001, 1(5):464-469.
48. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41(10):1407-1415.
49. Smith W.J., Drew R.H. Telavancin: a new lipoglycopeptide for gram-positive infections. Drugs Today (Barc) 2009, 45(3):159-173.
50. Mercier R.C., Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 2005, 3(3):325-332.
51. Stryjewski M.E., Corey G.R. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care 2009, 15(5):403-412.
52. Gorwitz R., Kruszon-Moran D., McAllister S., et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008, 197(9):1226-1234.
53. Navarro M.B., Huttner B., Harbarth S. Methicillin-resistant Staphylococcus aureus control in the 21st century: beyond the acute care hospital. Curr Opin Infect Dis 2008, 21(4):372-379.
54. Andrews J.I., Fleener D.K., Messer S.A., et al. Screening for Staphylococcus aureus carriage in pregnancy: usefulness of novel sampling and culture strategies. Am J Obstet Gynecol 2009, 201(4):396. e1-5.
55. Ringberg H., Cathrine Petersson A., Walder M., et al. The throat: an important site for MRSA colonization. Scand J Infect Dis 2006, 38(10):888-893.
56. Simor A.E., Phillips E., McGeer A., et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007, 44(2):178-185.
57. Harbarth S., Dharan S., Liassine N., et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999, 43(6):1412-1416.
58. Okano M., Noguchi S., Tabata K., et al. Topical gentian violet for cutaneous infection and nasal carriage with MRSA. International Journal of Dermatol 2000, 39(12):942-944.
59. Loveday H.P., Pellowe C.M., Jones S.R., et al. A systematic review of the evidence for interventions for the prevention and control of meticillin-resistant Staphylococcus aureus (1996-2004): report to the Joint MRSA Working Party (Subgroup A). J Hosp Infect 2006, 63(Suppl 1):S45-S70.
60. Walsh T.J., Standiford H.C., Reboli A.C., et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993, 37(6):1334-1342.
61. Lipsky B.A., Pecoraro R.E., Ahroni J.H., et al. Immediate and long-term efficacy of systemic antibiotics for eradicating nasal colonization with Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1992, 11(1):43-47.
62. Boyce J.M., Havill N.L., Maria B. Frequency and possible infection control implications of gastrointestinal colonization with methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005, 43(12):5992-5995.
63. Maraha B., van Halteren J., Verzijl J.M., et al. Decolonization of methicillin-resistant Staphylococcus aureus using oral vancomycin and topical mupirocin. Clin Microbiol Infect 2002, 8(10):671-675.
64. Silvestri L., Milanese M., Oblach L., et al. Enteral vancomycin to control methicillin-resistant Staphylococcus aureus outbreak in mechanically ventilated patients. Am J Infect Control 2002, 30(7):391-399.
65. Reichman O., Sobel J.D. MRSA infection of buttocks, vulva, and genital tract in women. Curr Infect Dis Rep 2009, 11(6):465-470.
66. Buehlmann M., Frei R., Fenner L., et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008, 29(6):510-516.
67. Elston D.M. How to handle a CA-MRSA outbreak. Dermatol Clin 2009, 27(1):43-48.
68. Elston D.M. Practical management tips for methicillin-resistant Staphylococcus aureus. Cutis 2008, 81(4):311-313.
69. CDC Guidelines Community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) Available at:, Accessed November 2, 2009. http://www.cdc.gov/ncidod/dhqp/ar_mrsa.html.
70. Schaffer A.C., Lee J.C. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 2009, 23(1):153-171.
71. Shinefield H., Black S., Fattom A., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002, 346(7):491-496.
72. Bloom B., Schelonka R., Kueser T., et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005, 24(10):858-866.
73. Weisman L.E., Fischer G.W., Thackray H.M., et al. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol 2009, 9(5):639-644.